\midlacknowledgments{
Data collection and sharing for this project was funded (in part) by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research \& Development, LLC.; Johnson \& Johnson Pharmaceutical Research \& Development LLC.; Lumosity; Lundbeck; Merck \& Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

The BLSA is supported by the Intramural Research Program, National Institute on Aging, NIH.

The BIOCARD study is supported by a grant from the National Institute on Aging (NIA): U19-AG03365. The BIOCARD Study consists of 7 Cores and 2 projects with the following members: (1) The Administrative Core (Marilyn Albert, Corinne Pettigrew, Barbara Rodzon); (2) the Clinical Core (Marilyn Albert, Anja Soldan, Rebecca Gottesman, Corinne Pettigrew, Leonie Farrington, Maura Grega, Gay Rudow, Rostislav Brichko, Scott Rudow, Jules Giles, Ned Sacktor); (3) the Imaging Core (Michael Miller, Susumu Mori, Anthony Kolasny, Hanzhang Lu, Kenichi Oishi, Tilak Ratnanather, Peter vanZijl, Laurent Younes); (4) the Biospecimen Core (Abhay Moghekar, Jacqueline Darrow, Alexandria Lewis, Richard O’Brien); (5) the Informatics Core (Roberta Scherer, Ann Ervin, David Shade, Jennifer Jones, Hamadou Coulibaly, Kathy Moser, Courtney Potter); the (6) Biostatistics Core (Mei-Cheng Wang, Yuxin Zhu, Jiangxia Wang); (7) the Neuropathology Core (Juan Troncoso, David Nauen, Olga Pletnikova, Karen Fisher); (8) Project 1 (Paul Worley, Jeremy Walston, Mei-Fang Xiao), and (9) Project 2 (Mei-Cheng Wang, Yifei Sun, Yanxun Xu.

Data collection and sharing for this project was provided by the Human Connectome Project (HCP; PI: Bruce Rosen, M.D., Ph.D., Arthur W. Toga, Ph.D., Van J. Weeden, MD). HCP funding was provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS). HCP data are disseminated by the Laboratory of Neuro Imaging at the University of Southern California.

Data collection and sharing for this project was provided by the International Consortium for Brain Mapping (ICBM; Principal Investigator: John Mazziotta, MD, PhD). ICBM funding was provided by the National Institute of Biomedical Imaging and BioEngineering. ICBM data are disseminated by the Laboratory of Neuro Imaging at the University of Southern California.

The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI Julie Schneider, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD).

Data was provided by OASIS-3. Longitudinal Multimodal Neuroimaging: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.

Data contributed from ROS/MAP/MARS was supported by NIA R01AG017917,\newline
P30AG10161, P30AG072975, R01AG022018, R01AG056405, UH2NS100599, UH3NS100599, R01AG064233, R01AG15819 and R01AG067482, and the Illinois Department of Public Health (Alzheimer’s Disease Research Fund). Data can be accessed at \url{www.radc.rush.edu}.

The data contributed from the Wisconsin Registry for Alzheimer’s Prevention was supported by NIA AG021155, AG0271761, AG037639, and AG054047.

This work was supported by the Alzheimer’s Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC) that is funded by NIA (U24 AG074855, U01 AG068057 and R01 AG059716).

The authors would like to thank Dr. Aaron Carass for helpful comments and feedback on the manuscript.
}